| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$26,360 ) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 000 | 3 | NIH | 12/8/2025 | $468,540 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295874 | Proteotoxic Metabolites in Genome Instability and Disease | 000 | 2 | NIH | 12/9/2025 | $519,032 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 11/21/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247883 | Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | 000 | 5 | NIH | 11/24/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI183604 | Role of GRAIL in B cell tolerance and B-cell mediated inflammation | 000 | 1 | NIH | 11/27/2025 | -$657,643 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 000 | 10 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA281701 | The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer | 000 | 3 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P40OD024628 | Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR) | 000 | 8 | NIH | 12/8/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | UH3CA276603 | Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial | 000 | 2 | NIH | 11/21/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DK126365 | The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer | 000 | 5 | NIH | 11/25/2025 | -$28,407 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DK108328 | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) | 000 | 10 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA251703 | Identifying the vulnerabilities in Mdm2 overexpressing cancer cells | 000 | 5 | NIH | 12/9/2025 | -$2 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA243698 | Modeling tumor heterogeneity and treatment resistance in small cell lung cancer | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA237384 | Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis | 000 | 5 | NIH | 11/28/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA228304 | Crosstalk Between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer | 000 | 7 | NIH | 12/4/2025 | -$3,484 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS116704 | Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment | 000 | 2 | NIH | 10/1/2025 | -$160,002 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251816 | Breaking down tumor immune privilege through targeted hypoxia reduction | 000 | 5 | NIH | 11/20/2025 | $0 |
| | 2026 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251608 | A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously | 000 | 5 | NIH | 12/2/2025 | -$8,911 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01GM132219 | Building a Diverse Biomedical Workforce Through Communication Across Difference | 000 | 5 | NIH | 10/1/2025 | -$6,516 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA256136 | Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study | 001 | 2 | NIH | 11/28/2025 | $39,634 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA256136 | Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults with Cancer: A two arm pilot study | 000 | 2 | NIH | 11/28/2025 | -$39,634 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MH120299 | Integrative Brain Network-Based Analysis for Heterogeneous and Multimodal | 000 | 5 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA237672 | Adoptive T Cell Therapy for Pancreatic Cancer | 000 | 5 | NIH | 12/8/2025 | -$8,288 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA231465 | Rigorous and reproducible mutational analysis of the urinary exosomal DNA | 000 | 5 | NIH | 12/2/2025 | -$117,989 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA240338 | Characterizing heterochromatin dysfunction as a driving alteration in cancer | 000 | 5 | NIH | 12/2/2025 | -$2,745 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA193522 | The Metabolic Basis of Cancer-Related Fatigue | 000 | 9 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA174798 | Endothelial-to-osteoblast transition in prostate cancer bone metastasis | 000 | 10 | NIH | 12/8/2025 | $0 |
| | 2026 | 2022 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01ES029680 | Mechanism of RAD51C fork protection and environmental carcinogenesis | 000 | 5 | NIH | 12/3/2025 | -$19,936 |
| | 2026 | 2022 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA221971 | Optimization and Evaluation of Anatomical Models of Liver Radiation Response | 000 | 5 | NIH | 11/25/2025 | -$11 |
| | 2026 | 2021 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA258134 | Impact of sugary drinks on gut microbiota and development of young-onset colorectal cancer | 000 | 2 | NIH | 11/18/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $217,758,380 ) (Continued on the next page) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 001 | 2 | NIH | 5/22/2025 | $18,933 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 2 | NIH | 2/13/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 001 | 3 | NIH | 5/22/2025 | $49,385 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 3 | NIH | 3/7/2025 | $444,485 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 1 | NIH | 3/12/2025 | $676,584 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA293160 | Evaluating Dietary Change and a Mediterranean Diet Intervention Among Medically Underserved Men with Prostate Cancer | 000 | 1 | NIH | 7/2/2025 | $210,003 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P01CA296429 | Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. | 000 | 1 | NIH | 8/19/2025 | $2,108,734 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA303904 | Dissecting clonal determinants of platinum/PARP inhibitor cross-resistance in ovarian cancer | 000 | 1 | NIH | 8/19/2025 | $164,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 000 | 5 | NIH | 3/3/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 001 | 5 | NIH | 5/23/2025 | $37,057 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 3 | NIH | 5/22/2025 | $49,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 3 | NIH | 2/13/2025 | $444,596 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 002 | 2 | NIH | 7/23/2025 | $175,256 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 001 | 2 | NIH | 5/9/2025 | $16,200 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 2 | NIH | 3/18/2025 | $145,800 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA302482 | MD Anderson Sarcoma SPORE | 000 | 1 | NIH | 8/19/2025 | $1,824,620 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R13CA306203 | Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment | 000 | 1 | NIH | 8/20/2025 | $10,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 001 | 5 | NIH | 5/23/2025 | $46,003 |
|
